Corticosteroids are the most common treatment for pediatric patients with alopecia areata (AA), but promising newer options like JAK inhibitors are emerging. This review highlights the importance of personalized treatment plans and maximizing response through combination therapies.
Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.
Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.